Y Intercept Hong Kong Ltd Has $2.06 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Y Intercept Hong Kong Ltd decreased its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 42.3% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 12,512 shares of the company's stock after selling 9,155 shares during the quarter. Y Intercept Hong Kong Ltd's holdings in Zoetis were worth $2,060,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Geode Capital Management LLC grew its position in Zoetis by 1.8% during the fourth quarter. Geode Capital Management LLC now owns 10,617,897 shares of the company's stock valued at $1,726,075,000 after purchasing an additional 190,137 shares in the last quarter. Wellington Management Group LLP grew its position in Zoetis by 78.5% during the fourth quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company's stock valued at $1,133,755,000 after purchasing an additional 3,059,255 shares in the last quarter. Northern Trust Corp grew its position in Zoetis by 13.3% during the fourth quarter. Northern Trust Corp now owns 6,426,394 shares of the company's stock valued at $1,047,052,000 after purchasing an additional 755,893 shares in the last quarter. Norges Bank purchased a new position in Zoetis during the fourth quarter valued at approximately $824,321,000. Finally, Unisphere Establishment grew its position in Zoetis by 7.3% during the fourth quarter. Unisphere Establishment now owns 4,800,000 shares of the company's stock valued at $782,064,000 after purchasing an additional 325,000 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Insider Activity

In other news, EVP Roxanne Lagano sold 652 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the sale, the executive vice president directly owned 15,129 shares of the company's stock, valued at approximately $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.18% of the company's stock.

Analyst Ratings Changes

ZTS has been the subject of several recent research reports. Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and reduced their price target for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. UBS Group reduced their price target on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Piper Sandler lifted their price target on Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Monday, May 12th. Finally, Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and reduced their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $204.63.

Zoetis Stock Performance

ZTS traded down $0.90 on Friday, hitting $151.92. The company had a trading volume of 3,326,080 shares, compared to its average volume of 2,967,721. The company's fifty day moving average price is $159.91 and its 200 day moving average price is $160.99. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.74 and a quick ratio of 1.04. The stock has a market cap of $67.64 billion, a price-to-earnings ratio of 27.28, a price-to-earnings-growth ratio of 2.52 and a beta of 0.91.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. The firm had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. During the same period in the previous year, the company earned $1.38 EPS. The company's revenue for the quarter was up 1.4% on a year-over-year basis. Equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.32%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's dividend payout ratio is currently 35.91%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.